🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Dr. Massimo Cristofanilli (@MCristofanill) for being selected as a mentor by ASCO as part of their new International Clinical Research Scholars (ICR) program in Latin America: bit.ly/411La22

The Cristofanilli CTC Laboratory team is involved with a number of abstracts at #SABCS24 this week. Learn more about their #research involvement below and stay tuned for a roundup of this work after the conference.

Dr. Vered Stearns shares findings from a #ClinicalTrial evaluating an anti-PD-L1 immune checkpoint inhibitor for early triple-negative #BreastCancer (#TNBC): bit.ly/3CXvdQw

WATCH: Dr. Vered Stearns chatted with OncLive.com about the role of carboplatin #chemotherapy for early-stage triple-negative #BreastCancer (TNBC) as demonstrated in a phase 3 #ClincialTrial bit.ly/41rLSWM

A new $2.3 million grant from the Centers for Disease Control and Prevention to improve equitable access to care, quality of life and survival outcomes for young people with all stages of breast cancer was recently awarded to Drs. Stearns and Cigler in our division of Hematology

A $2.3 million CDC grant will aid the initiative to improve care access and survival outcomes for young breast cancer patients. Drs. Tessa Cigler and Vered Stearns of Weill Cornell Breast Center will lead this effort focusing on diverse patients. More: bit.ly/3BWsaIb

Researchers from the Cristofanilli CTC Laboratory were involved with a number of abstracts presented at #SABCS24 on the role of circulating tumor cells (CTCs) in a variety of types of #BreastCancer, including invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC), and HER2+ #cancer.

Dr. Massimo Cristofanilli and collaborators from across Weill Cornell Medicine, Cristofanilli CTC Laboratory and Italy shared #research at #SABCS24 on how tumor cell-derived exomes impact the landscape of inflammatory #BreastCancer.

.Cristofanilli CTC Laboratory team members gave insights into their #research involvement on the use of circulating tumor DNA (#ctDNA) testing for both advanced and early-stage #BreastCancer at #SABCS24

This year’s World Cancer Day theme is "United by Unique." Our collaborative approach to cancer care ensures patients receive top evaluations and therapies, including advancements in precision medicine and immune-based treatments. We make the fight against cancer personal.

The oncology team NewYork-Presbyterian Brooklyn hosts an art open house each year to display art created by patients as part of the HEART (Healing and Empowerment through ART) program, which offers free art classes for #cancer patients: bit.ly/4joMBxU (cc: Alan B. Astrow)

Clinical research Weill Cornell Medicine NewYork-Presbyterian is dedicated to innovating, inspiring and transforming lives. On #ClinicalTrialsDay, some of our team members who support clinical research are sharing how we are Powered By Purpose. #CTD2025 ACRP - Assoc. of Clinical Research Profession

Dr. Emily Tonorezos, the Director of our #BreastCancer Survivorship Program, is presenting during a survivorship education session at #ASCO25 this afternoon. Learn more: bit.ly/4jqkm15

Dr. Massimo Cristofanilli explains #research presented during the plenary session at #ASCO25 for hormone receptor-positive #BreastCancer. These results are an important step forward in the management of endocrine resistance in this group of patients. bit.ly/3ZEFdqf

New York ➡️ Chicago! Excited to see some of our Weill Cornell Medicine @NYPHospital team members at #ASCO25, ready to connect and share insights! Weill Cornell Medicine Meyer Cancer Center WCMHemOncFellow WCM Lung Cancer WCM GI Cancer WCM GU Cancer Weill Cornell Breast Center WCM Cutaneous Oncology

ICYMI: Dr. Massimo Cristofanilli was involved with #research presented at #ASCO25 and concurrently published in NEJM on the use of liquid biopsy blood tests to detect treatment-resistant mutations in a subset of #BreastCancer. bit.ly/4jswHSB

📰“Doctors might one day use liquid biopsies to provide further answers when mammogram results are unclear… whose tumors are often missed by standard screenings” Dr. Massimo Cristofanilli, Weill Cornell Breast Center nbcnews.com/health/cancer/…

“This is the proof that precision medicine is changing the practice of breast oncology,” said Dr. Massimo Cristofanilli, discussing #research presented at #ASCO25 on the use of camizestrant at detection of ESR1 mutations in advanced #BreastCancer patients. bit.ly/4ngXftc

Honored to host CancerCast for Weill Cornell Medicine There is so much to learn and so much to talk about! Available on Apple Podcast, Spotify, or wherever you listen to podcasts! bit.ly/45BV0u0

WATCH: Dr. Massimo Cristofanilli spoke with CURE Today about #research targeting ESR1 mutations early on in an effort to improve #BreastCancer outcomes bit.ly/4e8AWS4